Aclaris Therapeutics, Inc.ACRSNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -53.18% | -47.58% | -39.32% | -35.76% | -24.09% |
| Gross Profit Growth | +77.80% | -100.81% | +70.07% | -108.52% | +42.47% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.81% | +34.49% | +72.20% | +71.94% | +71.78% |
| Weighted Average Shares Diluted Growth | +0.81% | +34.49% | +72.20% | +71.94% | +71.78% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -149.69% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -149.80% |
| Receivables Growth | -0.87% | +6.71% | -32.98% | -40.31% | +1264.43% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -16.47% | +11.61% | +13.80% | +17.43% | -3.76% |
| Book Value per Share Growth | -17.42% | -26.41% | -41.09% | -42.75% | -46.28% |
| Debt Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | -75.05% | -66.13% | +17.66% | +30.71% | +118.74% |
| SG&A Expenses Growth | -16.84% | -39.69% | -10.30% | +15.78% | -13.83% |